Sponsor Check › Issuer
Corporation · organized in DELAWARE · formed Over five years ago · FOSTER CITY, CA · SEC CIK 1852167
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 19, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:12 PM ET.
0 of 7 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Mar 31, 2021 D File 021-394218 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jul 29, 2024 D/A File 021-489534 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Feb 14, 2024 D File 021-505327 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Feb 14, 2024 D File 021-505329 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jul 8, 2025 D File 021-550950 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Apr 23, 2026 D File 021-581637 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 19, 2026 D File 021-601738 | $0 | $0 | $0 | None listed |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D filed Oct 19, 2026 SEC file no. 021-601738 · accession 0001852167-26-000002 |
|---|---|
| Raise progress | $12,000,000 sold of $12,000,000 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Oct 2, 2026 · Form D filed: Oct 19, 2026 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 22 days (0.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Debt; Other: Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Lindsay Mateo, Chief Executive Officer (Oct 19, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $12,000,000. Typical range: $2,000,000–$19,999,994. Investors: 5. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Apr 23, 2026 SEC file no. 021-581637 · accession 0001852167-26-000001 |
|---|---|
| Raise progress | $5,000,000 sold of $5,000,000 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Apr 10, 2026 · Form D filed: Apr 23, 2026 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 197 days (0.5 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Debt; Other: Convertible promissory note convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Lisa Alderson, Chief Executive Officer (Apr 23, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $5,000,000. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jul 8, 2025 SEC file no. 021-550950 · accession 0001852167-25-000001 |
|---|---|
| Raise progress | $25,425,442 sold of $27,000,000 offered (94%) · $1,574,558 remaining |
| Filing timing | Date of first sale: Jun 23, 2025 · Form D filed: Jul 8, 2025 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 488 days (1.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 9 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Debt; Other: Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Priscilla Huang, Senior Vice President of Finance, Treasurer and Secretary (Jul 8, 2025) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $27,000,000. Typical range: $2,000,000–$19,999,994. Investors: 9. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D/A (amendment) filed Jul 29, 2024 · amends 0001852167-23-000002 ↗ SEC file no. 021-489534 · accession 0001852167-24-000003 |
|---|---|
| Raise progress | $48,540,780 sold of $49,317,173 offered (98%) · $776,393 remaining |
| Filing timing | Date of first sale: Jul 28, 2023 · Form D filed: Jul 29, 2024 (367 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,184 days (3.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 11 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Lisa Alderson, Chief Executive Officer (Jul 27, 2024) |
| Changes vs prior filing | total sold: $28,031,993 → $48,540,780 total offering: $29,199,991 → $49,317,173 investors: 8 → 11 Compared with the D filed Aug 11, 2023 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $49,317,173. Typical range: $2,000,000–$19,999,994. Investors: 11. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 14, 2024 SEC file no. 021-505329 · accession 0001852167-24-000002 |
|---|---|
| Raise progress | $3,296,554 sold of $3,296,554 offered (100%) · $0 remaining The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer. |
| Filing timing | Date of first sale: Oct 10, 2023 · Form D filed: Feb 14, 2024 (127 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,110 days (3.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Lisa Alderson, Chief Executive Officer (Feb 11, 2024) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $3,296,554. Typical range: $2,000,000–$19,999,994. Investors: 3. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 14, 2024 SEC file no. 021-505327 · accession 0001852167-24-000001 |
|---|---|
| Raise progress | $1,187,700 sold of $1,187,700 offered (100%) · $0 remaining The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer. |
| Filing timing | Date of first sale: Jul 14, 2021 · Form D filed: Feb 14, 2024 (945 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,928 days (5.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Lisa Alderson, Chief Executive Officer (Feb 11, 2024) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $1,187,700. Typical range: $2,000,000–$19,999,994. Investors: 2. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Aug 11, 2023 SEC file no. 021-489534 · accession 0001852167-23-000002 |
|---|---|
| Raise progress | $28,031,993 sold of $29,199,991 offered (96%) · $1,167,998 remaining |
| Filing timing | Date of first sale: Jul 28, 2023 · Form D filed: Aug 11, 2023 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,184 days (3.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Scott Bratman, President (Aug 4, 2023) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $29,199,991. Typical range: $2,000,000–$19,999,994. Investors: 8. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Mar 31, 2021 SEC file no. 021-394218 · accession 0001852167-21-000001 |
|---|---|
| Raise progress | $29,999,988 sold of $59,999,976 offered (50%) · $29,999,988 remaining |
| Filing timing | Date of first sale: Mar 17, 2021 · Form D filed: Mar 31, 2021 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,047 days (5.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 7 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Scott Bratman, President, CEO (Mar 31, 2021) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $59,999,976. Typical range: $2,000,000–$19,999,994. Investors: 7. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 2 new offerings in the last 12 months · most recent filing Oct 19, 2026.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| Abraham Kometz | Director | CA | Apr 23, 2026 → Oct 19, 2026 | — |
| Alan Williams | Executive Officer | CA | Aug 11, 2023 → Oct 19, 2026 | — |
| Anne-Renee Hartman | Executive Officer | CA | Aug 11, 2023 → Oct 19, 2026 | — |
| Daniel Diniz De Carvalho | Executive Officer | CA | Aug 11, 2023 → Oct 19, 2026 | — |
| David Bonita | Director | CA | Aug 11, 2023 → Oct 19, 2026 | 4 other issuers |
| David Scheer | Executive Officer, Director | CA | Mar 31, 2021 → Oct 19, 2026 | — |
| Lindsay Mateo | Executive Officer, Director | CA | Apr 23, 2026 → Oct 19, 2026 | — |
| Maneesh Jain | Director | CA | Mar 31, 2021 → Oct 19, 2026 | 1 other issuer |
| Paul Brown | Director | CA | Aug 11, 2023 → Oct 19, 2026 | 2 other issuers |
| Robert Weisskoff | Director | CA | Aug 11, 2023 → Oct 19, 2026 | 5 other issuers |
| Lisa Alderson | Executive Officer, Director | CA | Aug 11, 2023 → Apr 23, 2026 | 1 other issuer |
| Scott Bratman | Executive Officer | CA | Mar 31, 2021 → Apr 23, 2026 | — |
| Andrew ElBardissi | Director | CA | Aug 11, 2023 → Jul 8, 2025 | 5 other issuers |
| Priscilla Huang | Executive Officer | CA | Aug 11, 2023 → Jul 8, 2025 | — |
| Karla Jarvis | Executive Officer | CA | Aug 11, 2023 → Jul 29, 2024 | — |
| Christopher Parker | Executive Officer | CA | Aug 11, 2023 | — |
| Anne-Renee Hartman Feldman | Executive Officer | CA | Mar 31, 2021 | — |
| Daniel De Carvalho | Executive Officer | A6 | Mar 31, 2021 | — |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on filings for 1 other issuer. Stated as a count only — many addresses are shared office buildings or registered agents.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Adela, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.